Lipoprotein glomerulopathy
Authors:
- 1 August 2011
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Lipidology
- Vol. 22 (4) , 262-269
Abstract
Lipoprotein glomerulopathy is a rare disorder characterized by proteinuria, renal insufficiency and disturbances in lipoprotein metabolism closely related to those observed in type III hyperlipidemia. Rare mutations in apolipoprotein E (apoE) gene may contribute to the pathogenesis of the disease. This article reviews the clinical and laboratory features of lipoprotein glomerulopathy, discusses the mechanisms that may be implicated in its pathogenesis and summarizes the currently available therapeutic options. During the past years two new apoE gene mutations were described in Caucasian patients, apoE Modena (Arg150→Cys) and apoE Las Vegas (Ala152→Asp), a finding indicating that the disease may be more common in white populations than initially thought. Results from case studies suggest that fibrates improve renal pathology and may result in the complete clinical remission of the disease. LDL-apheresis or immunoadsorption onto staphylococcal protein A may also have a role in refractory cases. Lipid glomerulopathy is a rare, poorly understood disorder with potentially detrimental consequences. The determination of the effects of apoE mutations on the structural and functional characteristics of the mature protein may provide new insights in the pathogenesis of the disease. Meanwhile, intensive lipid-lowering may reduce proteinuria and preserve renal function in this patient group.Keywords
This publication has 54 references indexed in Scilit:
- Renal lipid metabolism and lipotoxicityCurrent Opinion in Nephrology and Hypertension, 2010
- Common Apolipoprotein E Gene Mutations Contribute to Lipoprotein Glomerulopathy in ChinaNephron Clinical Practice, 2010
- Lipoprotein glomerulopathy treated with LDL-apheresis (Heparin-induced Extracorporeal Lipoprotein Precipitation system): a case reportJournal of Medical Case Reports, 2009
- Improvement of nephrotic syndrome by intensive lipid-lowering therapy in a patient with lipoprotein glomerulopathyClinical and Experimental Nephrology, 2009
- Successful treatment of patients with lipoprotein glomerulopathy by protein A immunoadsorption: a pilot studyNephrology Dialysis Transplantation, 2008
- Dyslipidemia in Chronic Kidney Disease: An Approach to Pathogenesis and TreatmentAmerican Journal of Nephrology, 2008
- Identification of Apolipoprotein E Guangzhou (Arginine 150 Proline), a New Variant Associated with Lipoprotein GlomerulopathyAmerican Journal of Nephrology, 2007
- Lipoprotein glomerulopathy-like disease in a patient with type III hyperlipoproteinemia due to apolipoprotein E2 (Arg158 Cys)/3 heterozygosityClinical and Experimental Nephrology, 2007
- Apolipoprotein E and renal diseaseAmerican Journal of Kidney Diseases, 2004
- Lipoprotein glomerulopathy: Significance of lipoprotein and ultrastructural featuresKidney International, 1999